CN105294713A - Velpatasvir intermediate and preparation method thereof - Google Patents

Velpatasvir intermediate and preparation method thereof Download PDF

Info

Publication number
CN105294713A
CN105294713A CN201510647298.XA CN201510647298A CN105294713A CN 105294713 A CN105294713 A CN 105294713A CN 201510647298 A CN201510647298 A CN 201510647298A CN 105294713 A CN105294713 A CN 105294713A
Authority
CN
China
Prior art keywords
compound
formula
iodine
bromine
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510647298.XA
Other languages
Chinese (zh)
Inventor
牟祥
刘念
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONSCIENECE PHARMACEUTICALS Ltd
Original Assignee
CONSCIENECE PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CONSCIENECE PHARMACEUTICALS Ltd filed Critical CONSCIENECE PHARMACEUTICALS Ltd
Priority to CN201510647298.XA priority Critical patent/CN105294713A/en
Publication of CN105294713A publication Critical patent/CN105294713A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention relates to a preparation method of a Velpatasvir (GS-5816) intermediate compound which serves as a hepatitis C resisting compound and is as shown in a formula 1, as well as preparation methods of a compound as shown in a formula 3 and a compound as shown in a formula 9. The compound as shown in the formula 3 and the compound as shown in the formula 9 are used for preparing a compound as shown in a formula 2 by nucleophilic substitution under the alkaline conditions; the compound as shown in the formula 2 is used for preparing the compound as shown in the formula 1 by a coupling reaction in the presence of a metal catalyst.

Description

Velpatasvir intermediate and preparation method thereof
Technical field
The present invention relates to Velpatasvir(GS-5816) intermediate and preparation method thereof.
Background technology
Velpatasvir (GS-5816) is the antiviral of new generation of lucky De Famo Saite limited liability company exploitation, and its structural formula is as follows.
Compound 2 is synthesis Velpatasvir (GS-5816) important intermediate, and current CN201280004097 reports its synthetic method (as route 1):
Route 1.Velpatasvir (GS-5816) synthetic route
There is following point in the method: the first, starting material is expensive, and the longer whole piece route cost that causes of route is higher.The second, in reaction, relate to the linked reaction of two step palladium chtalyst, dehalogenation impurity is more, take two, disposable pass imidazole ring, temperature is higher, and the side reaction of reaction is more simultaneously, purifying and difficulty thereof, at present by means of only crossing the means of purification purifying such as post, industrialization difficulty is larger.
Summary of the invention
In order to solve the expensive raw material price that existing issue exists, reaction scheme is long, cannot technology prepare Velpatasvir(GS-5816) problem, inventor is realized by technical scheme below: (as shown in Scheme 2) is prepared into compound 12 with compound 13 by halo, the linked reaction that metal catalytic occurs for compound 12 and compound 14 is prepared into compound 11, chemical combination 11 prepares compound 10 by reductive agent reduction, compound 10 is prepared into compound 9 at the hydroxy activated reagent react such as methylsulfonyl chloride or Tosyl chloride further, compound 8 and halogenating agent generation electrophilic substitution are prepared into compound 7, there is esterification in the basic conditions and prepare compound 6 in compound 7 and compound 15, ShiShimonoseki ring is there is and prepares compound 5 in compound 6 at ammonium acetate, compound 5 in the presence of an oxidizer oxydehydrogenation is prepared into compound 4, compound 4 hydrogenation under metal catalyst exists takes off benzyl and prepares compound 3, there is nucleophilic substitution reaction and prepare compound 2 in compound 3 and compound 9, linked reaction is there is and prepares compound 1 in compound 2 under palladium catalyst exists.
Route 2. compound 1 synthetic route
For a better understanding of the present invention, be explained in detail by concrete example below, should be noted that, following examples not limit the scope of the present invention, obviously, those of ordinary skill in the art according to illustrating, can make various correction and change to the present invention herein within the scope of the present invention, and these are revised and change and also include scope of the present invention in.
example 1
2-bromo-benzoic acid 402g is added in 3L reaction flask, nitrogen N-iodosuccinimide 500g, tetrahydrofuran (THF) 1L, vitriol oil 450g, room temperature reaction is after 5 hours, TLC (hexane: ethyl acetate 1:2) puts in plate to be controlled, iodine develops the color, raw material point disappears, after concentrated tetrahydrofuran (THF), add methyl alcohol 1L, sulfuric acid 250g back flow reaction, control in TLC (hexane: ethyl acetate 1:2), after intermediate reaction is complete, be cooled to 0-5 DEG C, drip 40% sodium hydroxide and be neutralized to neutrality, after concentrated solvent methyl alcohol, add extraction into ethyl acetate product, anhydrous magnesium sulfate drying, concentrate to obtain 12a product 610g, 89.5%.
example 2
In 5L reaction flask, under argon shield, 2-bromo-5-iodo-benzoic acid methyl esters 610g (12a), add toluene 3L, Potassium ethanoate 380g, connection pinacol borate 490g, 2-dicyclohexyl phosphorus-2'-methyl diphenyl 35g, palladium 20g, temperature rising reflux reacts 1 hour, TLC (hexane: ethyl acetate 1:2) puts in plate to be controlled, iodine develops the color, raw material point disappears, be cooled to room temperature, add potassiumphosphate 1200g and 715g iodoimidazole thing 14a, under argon shield, be warming up to back flow reaction to control in 2 hours, TLC (hexane: ethyl acetate 1:2) puts in plate to be controlled, iodine develops the color, raw material point disappears, be cooled to room temperature, separatory, after organic phase adds 1L diluted ethyl acetate, 2 times are washed with saturated nacl aqueous solution 2L, organic phase pad diatomite filtration, add N-acetyl-L-cysteine 100g, stirring at room temperature 12 hours, add 5% sodium hydroxide 2L to wash twice, dry, concentrated have solid to separate out, stop concentrated, drip 2L normal hexane stirring at room temperature crystallization 5 hours, filter to obtain 11a product 700g, yield 77%.
example 3
In 5L reaction flask; under nitrogen protection, add 11a700g, anhydrous tetrahydro furan 3.5L; be cooled to 0 to 5 DEG C; slowly add lithium aluminum hydride 70g in batches, finish, be naturally warming up to room temperature reaction 6 hours; sampling adds sal glauberi cancellation; TLC (hexane: ethyl acetate 1:4) puts in plate to be controlled, and iodine develops the color, and raw material point disappears; add 1200g sal glauberi cancellation reaction; attentional manipulation temperature, filter, filter cake 1L tetrahydrofuran (THF) washs; filtrate merges concentrated; obtain 10a product 600g, yield 93%, is directly used in the next step.
example 4
In 5L reaction flask, add 10a compound 550g under nitrogen protection, methylene dichloride 2.6L; diisopropylethylamine 460g is cooled to 0 to 5 DEG C, starts slowly to drip methylsulfonyl chloride 150g, finishes; maintain this thermotonus 1 hour, sampling TLC (hexane: ethyl acetate 1:4) is put in plate and is controlled, and starting material 10a disappears; slowly drip purified water and be neutralized to neutrality; separatory, organic phase anhydrous magnesium sulfate drying, concentrates to obtain 9a product 530g; yield 82.54%, is directly used in the next step.
example 5
Add 8 compound 700g in 5L reaction flask, add methylene dichloride 3.5L, methyl alcohol 250mL, add pyridinium tribromide 880g under room temperature in batches, finish reaction 30 minutes, TLC (hexane: ethyl acetate 1:4) puts in plate to be controlled, iodine develops the color, and raw material 8 disappearance, adds 6% sodium sulfite solution 1L and wash, 1L1N salt acid elution, purified water washing, to neutral, commonly used and is concentrated into about 2L, be cooled to room temperature, filter, obtain 7a product 800g, yield 87%.
example 6
7a compound 700g is added, compound 500g, cesium carbonate 560g in 5L reaction flask, 2-methyltetrahydrofuran 3.5L, be warming up to 50 DEG C of reactions 20 hours, TLC (hexane: ethyl acetate 1:4) puts in plate to be controlled, and starting material 7a point disappears, be cooled to room temperature, add 3.5L purified water to wash twice, anhydrous magnesium sulfate drying, concentrate to obtain 6a product 800g, yield 79.2%, is directly used in the next step.
example 7
6a compound 800g is added, ammonium acetate 1000g, ethylene glycol monomethyl ether 350mL in 5L reaction flask, toluene 3.5L temperature rising reflux reacts 2 hours, TLC (hexane: ethyl acetate 1:4) puts in plate to be controlled, and starting material 6a point disappears, and is cooled to room temperature, after adding ethyl acetate 3.5L dilution, add saturated sodium bicarbonate solution 3.5L to wash, saturated nacl aqueous solution 3.5L washs, anhydrous magnesium sulfate drying, concentrate to obtain 5a product 650g, yield 84.8%.
example 8
620g compound 5a is added in 5L reaction flask, Manganse Dioxide 1000g, methylene dichloride 4L, room temperature reaction 2 hours, sampling TLC (hexane: ethyl acetate 1:4) is put in plate and is controlled, and starting material point disappears, filter, filter cake adds 2L washed with dichloromethane, concentrates to obtain 4a product 600g, yield 97%.
example 9
4a compound 650g is added, dehydrated alcohol, Raney Ni 6.5g in 5L hydrogenation reaction cauldron, nitrogen replacement 3 times, hydrogen exchange three times, hydrogenation 5 hours between maintenance pressure 0.1 to 0.2MPa, sampling TLC (hexane: ethyl acetate 1:4) is put in plate and is controlled, and starting material 4a point disappears, and filters, after filtrate concentrates most of solvent, add toluene 1300mL, rising temperature for dissolving, slow cooling crystallization, obtain 3a product 500g, yield 95%.
example 10
3a compound 300g is added in 5L reaction flask, the 9a compound 450g of activation, DMF 600g, cesium carbonate 550g stirring at room temperature 12 hours sampling TLC (hexane: ethyl acetate 1:1) is put in plate and is controlled, starting material point disappears, after adding 3L diluted ethyl acetate, add 2L purified water and wash 2 times, anhydrous magnesium sulfate drying, concentrate to obtain 2a product 530g, yield 79.3%.
example 11
In 5L reaction flask, 2a compound 530g is added under argon shield, add [1, two (diphenylphosphino) ferrocene of 1'-] palladium chloride 25g, sodium-acetate 270g, N, dinethylformamide 2.6L, be warming up to 100 DEG C of reactions 6 hours, sampling TLC (hexane: ethyl acetate 1:1) is put in plate and is controlled, starting material 2a point disappears, be cooled to room temperature, proceed to 10L reaction flask, after adding 3L ethyl acetate and the dilution of 2L purified water, separatory, organic phase filters palladium removing after adding diatomite, organic phase saturated nacl aqueous solution washs, anhydrous magnesium sulfate drying, be concentrated into 2L, be cooled to 0 to 5 DEG C of filtration, filter cake vacuum-drying obtains 400g yellow solid 1a, yield 83.8%.
example 12
Under nitrogen protection, add 102g1a, add 500mL methylene dichloride to dissolve, add 1 of 4mol/LHCl, 4-dioxane solution 500mL, stirring at room temperature 1 hour, TLC (hexane: ethyl acetate 1:1) puts in plate to be controlled, starting material point disappears, stopped reaction, after concentrated solvent, add (R)-2-(methyloxycarbonylamino)-2-toluylic acid 29g, COMU60g, DMF500mL, diisopropylethylamine 223Ml, 25 DEG C are reacted 1 hour, after adding ethyl acetate 1L dilution, add 1L purified water and wash 2 times, anhydrous magnesium sulfate drying, after concentrated, add 500mL methyl alcohol to heat up 60 DEG C and dissolve, slow dropping 250mL purified water, separate out solid, finish, be cooled to 50 DEG C of insulations 1 hour, be cooled to room temperature to filter, concentrate to obtain Velpatasvir (GS-5816) product 90.5g, yield 78.2%.H-NMR(400MHz，CD 3OD)δ7.94-7.67(m,4H),7.59(d,J=9.1Hz,1H),7.52(s,1H),7.48-7.33(m,4H),7.11(d,J=18.7Hz,1H),5.68(d,J=6.3Hz,1H),5.48-5.33(m,1H),5.23(dd,J=24.1,15.7Hz,1H),5.17-5.03(m,3H),4.22(dd,J=17.0,9.6Hz,1H),4.16-4.01(m,1H),3.91(d,J=24.1Hz,1H),3.83-3.68(m,1H),3.68-3.59(m,3H),3.59-3.49(m,3H),3.38(ddd,J=15.9,9.6,5.7Hz,2H),3.28-3.14(m,5H),3.10(dd,J=14.0,8.2Hz,1H),3.00(dd,J=17.8,9.6Hz,1H),2.92(dd,J=14.5,6.7Hz,1H),2.73-2.41(m,2H),2.40-2.11(m,2H),2.11-1.83(m,2H),1.54(t,J=9.7Hz,2H),1.24(d,J=6.2Hz,1H),1.06(t,J=8.0Hz,1H),0.99(d,J=6.8Hz,1H),0.94(d,J=6.6Hz,2H),0.85(d,J=6.7Hz,2H)。

Claims (5)

1. anti-third liver medicine Velpatasvir(GS-5816) preparation method of midbody compound 1, it is characterized in that:
With formula 3 compound with formula 9 compound formula 2 compound is prepared in the basic conditions by nucleophilic substitution reaction,
Wherein: X 1for chlorine, bromine, iodine; R 2for Boc-, Cbz-; R 3for p-toluenesulfonyl, methylsulfonyl;
Formula 2 compound prepares formula 1 compound by linked reaction under metal catalyst exists,
。
2. compound 3 described in claim 1,
。
3. right wants compound 9 described in 1,
Wherein: X 1for chlorine, bromine, iodine; R 2for Boc-, Cbz-; R 3for p-toluenesulfonyl, methylsulfonyl.
4. the preparation method of compound 3 shown in claim 1, is characterized in that: formula 8 compound the formula for preparing 7 compound is reacted with halogenating agent,
Wherein: X 4for bromine, atomic iodine;
Formula 7 compound and formula 15 compound there is nucleophilic substitution reaction in the basic conditions and prepare formula 6 compound,
；
Formula 6 compound and ammonium acetate react the formula for preparing 5 compound,
；
Formula 5 dehydrogenation under oxygenant Manganse Dioxide exists prepares formula 4 compound,
；
Formula 4 compound is under metal catalyst exists, and hydrogenation debenzylation is prepared into formula 3 compound,
。
5. the preparation method of compound 9 described in claim 1, is characterized in that:
Halogenating agent and formula 13 compound generation electrophilic substitution are prepared into formula 12 compound,
Wherein: X 1, X 2independently selected from chlorine, bromine, iodine;
Formula 12 compound and formula 14 compound formula 11 compound is prepared at Phosphine ligands and palladium acetate catalyst existent condition,
Wherein: X 1for chlorine, bromine, iodine; X 3for bromine, iodine; R 2for Boc-, Cbz-;
Formula 11 is reduced in the presence of a reducing agent and is prepared into formula 10 compound,
Wherein: X 1for being chlorine, bromine, iodine;
Formula 10 compound and hydroxy activated reagent react are prepared into formula 9 compound,
Wherein: X 1, R 2as defined above; R 3for p-toluenesulfonyl, methylsulfonyl.
CN201510647298.XA 2015-10-09 2015-10-09 Velpatasvir intermediate and preparation method thereof Pending CN105294713A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510647298.XA CN105294713A (en) 2015-10-09 2015-10-09 Velpatasvir intermediate and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510647298.XA CN105294713A (en) 2015-10-09 2015-10-09 Velpatasvir intermediate and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105294713A true CN105294713A (en) 2016-02-03

Family

ID=55192618

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510647298.XA Pending CN105294713A (en) 2015-10-09 2015-10-09 Velpatasvir intermediate and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105294713A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801553A (en) * 2016-04-12 2016-07-27 爱斯特（成都）生物制药股份有限公司 Preparation method of benzochromene derivative
CN106220639A (en) * 2016-07-22 2016-12-14 上海众强药业有限公司 A kind of Wei Patawei intermediate novel crystal forms
WO2017060820A1 (en) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN107573355A (en) * 2016-11-30 2018-01-12 上海博志研新药物技术有限公司 Wei Patawei, wherein mesosome and preparation method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046114A (en) * 1955-03-01 1962-07-24 Azoplate Corp Diazo compounds and printing plates manufactured therefrom
CN102448956A (en) * 2009-03-30 2012-05-09 百时美施贵宝公司 Hepatitis c virus inhibitors
CN102596936A (en) * 2009-05-13 2012-07-18 吉里德科学公司 Antiviral compounds
CN103328480A (en) * 2011-11-16 2013-09-25 吉利德科学公司 Condensed imidazolylimidazoles as antiviral compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046114A (en) * 1955-03-01 1962-07-24 Azoplate Corp Diazo compounds and printing plates manufactured therefrom
CN102448956A (en) * 2009-03-30 2012-05-09 百时美施贵宝公司 Hepatitis c virus inhibitors
CN102596936A (en) * 2009-05-13 2012-07-18 吉里德科学公司 Antiviral compounds
CN103328480A (en) * 2011-11-16 2013-09-25 吉利德科学公司 Condensed imidazolylimidazoles as antiviral compounds

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060820A1 (en) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN105801553A (en) * 2016-04-12 2016-07-27 爱斯特（成都）生物制药股份有限公司 Preparation method of benzochromene derivative
CN105801553B (en) * 2016-04-12 2018-06-19 爱斯特（成都）生物制药股份有限公司 A kind of preparation method of Benzochromene derivatives
CN106220639A (en) * 2016-07-22 2016-12-14 上海众强药业有限公司 A kind of Wei Patawei intermediate novel crystal forms
CN107573355A (en) * 2016-11-30 2018-01-12 上海博志研新药物技术有限公司 Wei Patawei, wherein mesosome and preparation method
CN107674062A (en) * 2016-11-30 2018-02-09 上海博志研新药物技术有限公司 Anti- hepatitis pharmaceutical intermediate, preparation method and application
CN107759577A (en) * 2016-11-30 2018-03-06 上海博志研新药物技术有限公司 GS5816 intermediates, preparation method and application
CN107573355B (en) * 2016-11-30 2020-03-17 上海博志研新药物技术有限公司 Vipatasvir, intermediate and preparation method thereof
CN107759577B (en) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 GS5816 intermediate, preparation method and application
CN107674062B (en) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 Anti-hepatitis C drug intermediate, preparation method and application

Similar Documents

Publication Publication Date Title
CN105294713A (en) Velpatasvir intermediate and preparation method thereof
CN105358517B (en) The method that 2,3,5 trimethylbenzoquinones are prepared by the oxidation of 2,3,6 pseudocuminols
CN104650142B (en) A kind of preparation method of fosaprepitant dimeglumine
CN108794397A (en) A kind of his synthetic methods and its midbody compound of Luo Shasi
CN115368272A (en) Preparation method of 4-cyano-2-methoxybenzaldehyde
CN102344345A (en) Preparation method of arylene ether compound
CN110183445A (en) The synthetic method of Moxifloxacin and its derivative
CN104844593A (en) Synthetic method for Apixaban drug intermediate
CN101735300B (en) Method for preparing 6beta,7beta-methylene-steride-3beta,5beta-diol
CN104781231B (en) The method for preparing travoprost
CN104974057B (en) The preparation method and important intermediate of a kind of bromfenac sodium
CN106046077A (en) Tulathromycin A synthesis method
CN107108675A (en) The method for preparing diosmin
CN103012266B (en) Preparation method of 7-chloro-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine
CN109293478B (en) Method for preparing tetrafluorobenzyl alcohol
CN106588739A (en) Trans-3-hydroxy-L-proline preparation method
CN112939814B (en) Preparation method of deuterated dacarbazine intermediate
CN112125942A (en) Synthetic method of abiraterone acetate and intermediate thereof
CN107325133A (en) A kind of synthetic method of the deoxidation D ribose of 1,2,3 3 O acetyl group 5
CN103896938B (en) A kind of preparation method of succsinic acid YM-905
CN104829588B (en) A kind of Preparation Method And Their Intermediate of benzo [b] thiophene
CN104961675A (en) Preparation method of isavuconazole intermediate
CN105646634A (en) Preparation method of impurities of obeticholic acid
CN102093247B (en) Preparation method of 2-methyl-4-N-(2-methylbenzoyl)benzoic acid
CN103508883B (en) Method for synthesizing roflumilast intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
CB02 Change of applicant information

Address after: Jiulongpo Branch Park Science Park four street 400039 six Chongqing City No. 70 standard factory building 4 floor IJ

Applicant after: CONSCIENECE PHARMACEUTICALS LTD.

Address before: Jiulongpo Branch Park Science Park four street 400039 six Chongqing City No. 70 standard factory building 4 floor IJ

Applicant before: Conscienece Pharmaceuticals Ltd.

COR Change of bibliographic data
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160203

WD01 Invention patent application deemed withdrawn after publication